Hong Kong · Delayed Price · Currency is HKD Shanghai Bao Pharmaceuticals Company Description
Shanghai Bao Pharmaceuticals Co., Ltd. operates as a clinical-stage biotechnology company.
The company uses synthetic biology technology to develop and deliver recombinant biologic drugs in Mainland China, Hong Kong, Macau, and Taiwan.
Its products include KJ017, a recombinant human hyaluronidase; KJ103, an recombinant immunoglobulin G (IgG)-degrading enzyme; SJ02, a long-acting recombinant human follicle-stimulating hormone carboxyl-terminal peptide fusion protein (FSH-CTP); BJ044, a recombinant ulinastatin developed through synthetic biology; BJ007, a SC administered ceftriaxone sodium for the treatment of bacterial infections; and KJ101, a recombinant human chymotrypsin developed through synthetic biology.
The company also develops drug design platform, chassis cell engineering platform, and comprehensive bioprocessing platform.
The company sells its products under the Bao Pharma brand name. Shanghai Bao Pharmaceuticals Co., Ltd. was founded in 2019 and is based in Shanghai, China.
| Country | China |
| Founded | 2019 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 354 |
| CEO | Wang Zheng |
Contact Details
Address: No. 28 Luoxin Road Shanghai China | |
| Phone | 86 21 5669 6602 |
| Website | baopharma.com |
Stock Details
| Ticker Symbol | 2659 |
| Exchange | Hong Kong Stock Exchange |
| Fiscal Year | January - December |
| Reporting Currency | CNY |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Wang Zheng | Co-Founder, Chief Executive Officer and Executive Director |
| Dr. Liu Yanjun | Co-Founder and Executive Chairman |
| Tan Jingwei | Executive Director and Director of Internal Control |
| Li Cui | Chief Financial Officer, Joint Company Secretary and Executive Director |
| Haiman Fong | Joint Company Secretary |
| Yuhua Sun | Deputy General Manager |